奥马环素和五种对照药物对瑞典斯德哥尔摩艰难梭菌当代菌型的活性。
Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden.
机构信息
Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutegrid.4714.6t, Stockholm, Sweden.
Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
出版信息
Microbiol Spectr. 2021 Oct 31;9(2):e0144021. doi: 10.1128/Spectrum.01440-21. Epub 2021 Oct 6.
Abstract
Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects. The activity of omadacycline and five comparators was assessed with agar dilution on a 2015-to-2018 collection of 65 C. difficile isolates from Sweden. Omadacycline demonstrated activity against the contemporary ribotypes of C. difficile, and further clinical investigation is needed. Evaluating the activity of novel antimicrobials like omadacycline is of great interest, as a reliable and efficient antimicrobial treatment for Clostridioides difficile infections is in demand.
摘要
艰难梭菌感染是一个日益严峻的临床挑战。新型化合物奥马环素是一种有潜力的治疗选择，因为许多抗生素由于成本和副作用的原因，其活性有限或很少使用。奥马环素和五种对照药物的活性通过琼脂稀释法在 2015 年至 2018 年期间从瑞典采集的 65 株艰难梭菌分离株中进行了评估。奥马环素对当前艰难梭菌的核糖体型具有活性，需要进一步的临床研究。评估奥马环素等新型抗菌药物的活性具有重要意义，因为人们迫切需要一种可靠和有效的抗艰难梭菌感染的抗菌治疗方法。
相似文献
1
Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden.奥马环素和五种对照药物对瑞典斯德哥尔摩艰难梭菌当代菌型的活性。
Microbiol Spectr. 2021 Oct 31;9(2):e0144021. doi: 10.1128/Spectrum.01440-21. Epub 2021 Oct 6.
2
Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile.新型四环素类似物奥马环素及对照药物对艰难梭菌的活性
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00522-20.
3
Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials.艰难梭菌对奥马环素和比较抗菌药物的药敏性。
J Antimicrob Chemother. 2023 Jul 5;78(7):1779-1784. doi: 10.1093/jac/dkad170.
4
Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.瑞典一家大学医院中艰难梭菌的抗菌药物敏感性模式及其与PCR核糖型的关系。
Antimicrob Agents Chemother. 2006 May;50(5):1890-2. doi: 10.1128/AAC.50.5.1890-1892.2006.
5
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.体外研究依拉环素对常见艰难梭菌核糖体分型的活性。
J Antimicrob Chemother. 2020 Oct 1;75(10):2879-2884. doi: 10.1093/jac/dkaa289.
6
Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013.2011年至2013年美国艰难梭菌分离株的菌株类型及抗菌药物耐药模式
Antimicrob Agents Chemother. 2014 Jul;58(7):4214-8. doi: 10.1128/AAC.02775-13. Epub 2014 Apr 21.
7
Molecular characterization of Clostridioides difficile ribotype 027 in a major Chinese hospital.在中国一家大型医院中艰难梭菌 027 型的分子特征。
J Microbiol Immunol Infect. 2021 Dec;54(6):1179-1183. doi: 10.1016/j.jmii.2021.01.003. Epub 2021 Jan 28.
8
Antimicrobial resistance in Clostridioides difficile.艰难梭菌中的抗菌药物耐药性。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2459-2478. doi: 10.1007/s10096-021-04311-5. Epub 2021 Aug 24.
9
Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea.研究显示，奥马环素对艰难梭菌具有体外活性，并在艰难梭菌相关性腹泻的仓鼠模型中进行了初步疗效评估。
J Glob Antimicrob Resist. 2022 Sep;30:96-99. doi: 10.1016/j.jgar.2022.04.019. Epub 2022 Apr 29.
10
A US-based national surveillance study for the susceptibility and epidemiology of isolates with special reference to ridinilazole: 2020-2021.一项基于美国的全国性监测研究，旨在调查具有特殊参考意义的利奈唑胺敏感性和流行病学的 分离株：2020-2021 年。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0034923. doi: 10.1128/aac.00349-23. Epub 2023 Sep 20.
引用本文的文献
1
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin.一项I期试验，比较从接受奥马环素或万古霉素治疗的人类受试者收集的粪便中胆汁酸和短链脂肪酸的变化。
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0125124. doi: 10.1128/aac.01251-24. Epub 2025 Jan 17.
2
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).抗菌药物新视角：奥马环素用于社区获得性肺炎、皮肤及软组织感染和非结核分枝杆菌（重点论述）
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0108724. doi: 10.1128/aac.01087-24. Epub 2025 Jan 16.
3
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers.口服奥马环素与万古霉素在健康志愿者中的粪便药代动力学和肠道微生物组效应。
J Infect Dis. 2024 Jan 12;229(1):273-281. doi: 10.1093/infdis/jiad537.
4
Omadacycline and : A Systematic Review of Preclinical and Clinical Evidence.奥马环素与：临床前和临床证据的系统评价。
Ann Pharmacother. 2023 Feb;57(2):184-192. doi: 10.1177/10600280221089007. Epub 2022 Jun 3.
本文引用的文献
1
Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile.新型四环素类似物奥马环素及对照药物对艰难梭菌的活性
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00522-20.
2
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.奥马环素：一种新型口服和静脉注射氨甲基环素抗生素药物。
Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4.
3
Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence.替加环素治疗艰难梭菌感染患者：临床证据的更新。
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053-1058. doi: 10.1007/s10096-019-03756-z. Epub 2020 Jan 11.
4
The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.奥马环素治疗急性细菌感染的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Medicine (Baltimore). 2019 Dec;98(51):e18426. doi: 10.1097/MD.0000000000018426.
5
Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.口服和静脉注射奥马环素的药代动力学和药效学。
Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S16-S22. doi: 10.1093/cid/ciz309.
6
Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon.奥马环素对肠道微生物组的暴露在模拟人体近端、中段和远端结肠的模型中不会引起艰难梭菌的增殖或毒素产生。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01581-18. Print 2019 Feb.
7
Activities of Omadacycline and Comparators against Anaerobic Bacteria.奥马环素及对照药物对厌氧菌的活性。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.00047-18. Print 2018 Apr.
8
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.作为 2016 年 SENTRY 抗菌药物监测计划的一部分，对来自美国和欧洲的临床分离株进行了奥马环素活性测试的监测。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02327-17. Print 2018 Apr.
9
Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.成人艰难梭菌相关性腹泻的抗生素治疗
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD004610. doi: 10.1002/14651858.CD004610.pub5.
10
Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methods.采用琼脂稀释法与肉汤微量稀释法测定艰难梭菌最低抑菌浓度的比较。
Anaerobe. 2017 Apr;44:73-77. doi: 10.1016/j.anaerobe.2017.02.006. Epub 2017 Feb 7.
Zotero 插件